GlassScriptPhysician profile
Madalyn Chaumont
NPI 1295307221
$9,973.70
in general payments reported to CMS, 2019-2025
24 companies · $2,147 in 2025
The $2,147 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $329 · 2022: $1,790 · 2023: $2,829 · 2024: $2,878 · 2025: $2,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,684 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,683.81 |
| Education | $171.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,077.10 | 2022-2025 | |
| Janssen Biotech, INC. | $1,277.08 | 2022-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,141.62 | 2021-2025 | Trulance, Xifaxan, Relistor |
| Gilead Sciences, INC. | $975.14 | 2022-2025 | Epclusa, Livdelzi |
| Intercept Pharmaceuticals, INC. | $899.60 | 2021-2025 | Ocaliva |
| Ardelyx, INC. | $742.68 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $588.47 | 2022-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $504.72 | 2022-2025 | Entyvio |
| Celgene Corporation | $343.33 | 2022-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $307.47 | 2024-2025 | Iqirvo, Bylvay |
| Phathom Pharmaceuticals, INC. | $294.42 | 2024-2025 | Voquezna |
| Pfizer INC. | $270.07 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $112.55 | 2022 | |
| Medtronic, INC. | $90.95 | 2022 | |
| Nestle Healthcare Nutrition INC. | $59.84 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $53.74 | 2023-2024 | Suflave, Sutab |
| Ferring Pharmaceuticals INC. | $50.65 | 2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $46.15 | 2024 | |
| Lilly USA, LLC | $34.39 | 2025 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.33 | 2023 | Cyltezo |
| Novo Nordisk INC | $29.91 | 2025 | Wegovy |
| Genentech USA, INC. | $19.21 | 2021 | |
| Merck Sharp & Dohme LLC | $11.80 | 2022 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madalyn Chaumont listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.